摘要 |
Compounds of formula (I) are disclosed, wherein: A is a fibrinogen antagonist template; W is a linking moiety of the form -(CHR<g>)a-U-(CHR<g>)b-V-; Q<1>, Q<2>, Q<3> and Q<4> are independently N or C-R<y>, provided that no more than one of Q<1>, Q<2>, Q<3> and Q<4> is N; R' is H or C1-6alkyl, C3-7cycloalkyl-C0-6alkyl or Ar-C0-6alkyl; R<g> is H or C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl or Ar-C0-6alkyl; R<k> is R<g>, -C(O)R<g> or -C(O)OR<g> R<i> is H, C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl, Ar-C0-6alkyl, Het-C0-6alkyl-U'-C1-6alkyl, C3-7cycloalkyl-C0-6alkyl-U'-C1-6alkyl or Ar-C0-6alkyl-U'-C1-6alkyl; R<y> is H, halo, -OR<g>, -SR<g>, -CN, -NR<g>R<k>, -NO2, -CF3, CF3S(O)r-, -CO2R<g>, -COR<g> or -CONR<g>2, or C1-6alkyl optionally substituted by halo, -OR<g>, -SR<g>, -CN, -NR<g>R'', -NO2, -CF3, R'S(O)3-, -CO2R<g>, -COR<g> or -CONR<g>2; U and V are absent or CO, CR<g>2, C(=CR<g>2), S(O)c, O, NR<g>, CR<g>OR<g>, CR<g>(OR<k>)CR<g>2, CR<g>2CR<g>(OR<k>), C(O)CR<g>2, CR<g>2C(O), CONR<i>, NR<i>CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR<g>, NR<g>C(S), S(O)2NR<g>, NR<g>S(O)2N=N, NR<g>NR<g>, NR<g>CR<g>2, NR<g>CR<g>2, CR<g>2O, OCR<g>2, CR<g>=CR<g>, CC, Ar or Het; a is 0, 1, 2 or 3; b is 0, 1 or 2; c is 0, 1 or 2; r is 0, 1 or 2; and u is 0 or 1; or pharmaceutically acceptable salts thereof, which are vitronectin receptor antagonists useful in the treatment of osteoporosis.
|
申请人 |
SMITHKLINE BEECHAM CORPORATION;ALI, FADIA, E.;BONDINELL, WILLIAM, E.;KEENAN, RICHARD, M.;KU, THOMAS, WEN, FU;MILLER, WILLIAM, H.;SAMANEN, JAMES |
发明人 |
ALI, FADIA, E.;BONDINELL, WILLIAM, E.;KEENAN, RICHARD, M.;KU, THOMAS, WEN, FU;MILLER, WILLIAM, H.;SAMANEN, JAMES |